GlobeNewswire

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/11/2026
NAARDEN, the Netherlands and MIAMI, Nov. 06, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral [...]
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06/11/2026
NEW YORK, Nov. 06, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (the “Company”) (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer [...]
National Tirzepatide Online Telehealth Provider Ozari Health Launches Ozari Select Monthly Plan in All 50 States
06/11/2026
Ozari Select gives patients in every state, including California, month-to-month access to compounded tirzepatide at $235 and compounded semaglutide at $175, with a choice of three formulations, two named US-licensed [...]
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/11/2026
CAMBRIDGE, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core [...]
LeMaitre to Participate in Upcoming Investor Conferences
06/11/2026
BURLINGTON, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will participate in three upcoming investor conferences. Stifel 2026 Healthcare Conference [...]
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/11/2026
BRISBANE, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on November 2, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera [...]
Spyre Therapeutics Announces Grants of Inducement Awards
06/11/2026
WALTHAM, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate [...]
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2026
06/11/2026
Conference Call Scheduled for Friday, November 13, 2026 at 9:00 AM ET PORTLAND, Maine, Nov. 06, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics [...]
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/11/2026
MALVERN, Pa., Nov. 06, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today [...]
Amwell makes grant to new employees under inducement plan
06/11/2026
BOSTON, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, announces that on November 6, Amwell made grants of [...]
Entera Announces Third Quarter 2026 Financial Results and Business Updates
06/11/2026
Clinical Preparations Advanced for EB613 Phase 3 Osteoporosis Study, with First Site Activation Expected in Late 2026 Clinical and Commercial Leadership Expanded with Appointment of Senior Executives and Directors EB613 [...]
Sanuwave Will Host a Conference Call on November 11, 2026 at 8:30 AM (ET) to Present Q3 2026 Financial Results
06/11/2026
EDEN PRAIRIE, Minn., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live [...]
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
06/11/2026
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 06, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of [...]
Surrozen to Present at Upcoming Healthcare Investor Conference
06/11/2026
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling [...]
Confluent Medical Technologies Acquires Northern Nitinol, Expanding Advanced Nitinol Rapid Prototyping Capabilities
06/11/2026
Acquisition Expands Confluent's Nitinol Rapid Prototyping And Technical Knowledge While Strengthening Supply Chain Resilience For Next-generation Devices. SCOTTSDALE, Ariz., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Confluent [...]
Chemed Corporation Declares Quarterly Dividend of 70 Cents
06/11/2026
CINCINNATI, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (NYSE: CHE ) announced today that the Board of Directors has declared a quarterly cash dividend of 70-cents per share on the Company’s capital stock, [...]
Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social
06/11/2026
Information relative au nombre total de droits de vote et d’actions composant le capital social Dijon, France 06 novembre 2026 (17h45 CEST) -- CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ) , la Speciality Pharma qui [...]
Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social
06/11/2026
Information relative au nombre total de droits de vote et d’actions composant le capital social Dijon, France 06 novembre 2026 (17h45 CET) -- CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ) , la Speciality Pharma qui [...]
Immunocore presents promising data from Phase 1/2 trial cohort evaluating brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma
06/11/2026
In 17 first-line patients treated with the combination, the estimated two-year overall survival (OS) rate was 70% - Median OS was not reached at a median follow-up of 29 months and 10 patients remained on study Majority [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum